OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium
Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, βON THE HORIZON.β OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]